Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Clin Cancer Res. 2011 Jun 8;17(15):4996–5004. doi: 10.1158/1078-0432.CCR-10-3406

Figure 2. HNC patients display increased p70S6K phosphorylation following cetuximab treatment.

Figure 2

Twenty-one HNC tumor samples obtained prior to treatment with cetuximab (N=14) and/or following cetuximab therapy (N=7) were arrayed on a TMA and stained with an antibody directed against phospho-p70S6K (T421/S424). (A) The intensity of staining and the percentage of tumor cells that stained positively were determined and a composite score was calculated. The average composite score of pre-cetuximab and post-cetuximab tissues were graphed. (B) Expression of phospho-p70S6K in paired tissue (pre- and post-cetuximab treatment) from two HNC patients was assessed.